RxDoctor Payments Data

Lauren Franklin, MD

Family Medicine · Crestview, FLNPI 1043298284

Payments from drug & device makers

$443in general payments, 2019–2025

Across 22 payments — averaging $20.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$141
  • Novo Nordisk$115
  • AstraZeneca$87
  • Merck$31
  • Amarin Pharma, Inc.$30
  • GSK$14
  • plus $24 from 2 others

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$443 in reported general payments places this provider in the 45th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$36,188
Medicare patients
146
Services billed
435

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide59$94,444
EliquisApixaban33$29,630
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$25,448
MounjaroTirzepatide16$25,319
LinzessLinaclotide18$21,433
JardianceEmpagliflozin12$18,445
SymbicortBudesonide/Formoterol Fumarate12$4,538
Omeprazole183$3,349
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$2,501
SynthroidLevothyroxine Sodium37$2,148
Albuterol Sulfate HfaAlbuterol Sulfate85$1,792
Levothyroxine Sodium195$1,644
Atorvastatin Calcium272$1,472
Losartan Potassium151$1,242
Ventolin HfaAlbuterol Sulfate16$1,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$115$94,44459 claims
PfizerEliquis$12$29,63033 claims
GSKTrelegy Ellipta$14$25,44827 claims
AbbVieLinzess, Synthroid$12$23,58055 claims
AstraZenecaSymbicort$87$4,53812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →